Terns Pharmaceuticals, Inc. - Common Stock (TERN)

Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but reporting cases of drug-induced liver injury.

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

They could ride the wave of the hottest therapeutic area in the industry.

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.

This biotech's data suggests that it could have an advantage in its target market.

Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the highest dose.